CEP170 and non-small cell lung carcinoma: These assays showed a significant reduction in the binding of TBK1 to CEP170 in H460 NSCLC cells treated with the CEP170 peptide–penetratin conjugate (Fig. 7e), which was also evident by the reduced number of foci in CEP-peptide-treated cells (average of 9 foci per cell) versus Scr-peptide-treated cells (33 foci per cell) (Fig. 7f).